Welcome
to-BBB is a clinical stage biotechnology company focusing on enhanced drug delivery across the blood-brain barrier. The company is developing novel treatments for devastating brain disorders, such as brain cancer, neurodegenerative diseases and lysosomal storage diseases, by combining existing drugs with the G-Technology®, to-BBB's proprietary brain delivery platform.
Read more
Meet us at
Neurotech Investing & Partnering Conference 2012 - Boston
» 21 May 2012
LACDR Spring Symposium 2012 - Amsterdam
» 22 May 2012
Biomarkers World Europe - London
» 22 May 2012
This technology combines the widely used drug delivery approach of PEGylated liposomes with the endogenous tripeptide glutathione as targeting ligand in a novel and safe way. Together with several top tier pharma and biotech companies, to-BBB is investigating the versatility of the G-Technology® for drugs that are unable to reach the brain within a tolerable therapeutic window. to-BBB is applying the G-Technology for the delivery of doxorubicin for the treatment of brain cancer as its internal lead product 2B3-101. to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).
close
.png){kind=small}
.png){kind=small}
.png){kind=small}